Literature DB >> 8514481

Whither the rationale for thrombolytic agent administration? A retrospective review of traditional intuitive decision-making using a decision analysis model.

J G Kellett1, J O'Riordan.   

Abstract

Of 50 consecutive patients admitted to Nenagh Hospital coronary care unit 50 per cent did not develop a myocardial infarction. Only 10 patients had definite evidence of infarction on admission. Of the 40 remaining patients, only 15 subsequently developed electrocardiographic and enzymatic confirmation of infarction. Streptokinase was administered to 5 patients who did not infarct, and was not given to 10 patients who did. These decisions to use or withhold thrombolytic therapy were retrospectively reviewed using a computer programme incorporating a decision analysis of the benefits and risks of thrombolysis. The programme examined four scenarios that used different estimates of the chance of death from infarction (pdiMI), and different safety profiles of thrombolytics. The scenario that assumed the worst safety profile and estimated pdiMI from patient age would have recommended thrombolytic treatment to the most with, and to the least without, acute infarction (i.e. 60 per cent of patients with an infarct and 8 per cent without an infarct would have been treated). Depending on the scenario assumed, the traditional intuitive method of decision-making gained from 0.08 and 0.25 quality adjusted life years (QALY's) for the average patient. Had decision analysis been used to guide these decisions these gains would have been enhanced by from 0.21 to 0.28 QALY's per patient, regardless of scenario used.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8514481     DOI: 10.1007/BF02942102

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  24 in total

Review 1.  Hemorrhagic complications of long-term anticoagulant therapy.

Authors:  M N Levine; G Raskob; J Hirsh
Journal:  Chest       Date:  1989-02       Impact factor: 9.410

2.  Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).

Authors:  R G Wilcox; G von der Lippe; C G Olsson; G Jensen; A M Skene; J R Hampton
Journal:  Lancet       Date:  1988-09-03       Impact factor: 79.321

3.  Economics of coronary artery bypass grafting.

Authors:  A Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-03

4.  A computer protocol to predict myocardial infarction in emergency department patients with chest pain.

Authors:  L Goldman; E F Cook; D A Brand; T H Lee; G W Rouan; M C Weisberg; D Acampora; C Stasiulewicz; J Walshon; G Terranova
Journal:  N Engl J Med       Date:  1988-03-31       Impact factor: 91.245

5.  Enterococcal endocarditis and penicillin allergy. Which drug for the bug?

Authors:  D A Plante; S G Pauker
Journal:  Med Decis Making       Date:  1983       Impact factor: 2.583

Review 6.  Selection of patients with acute myocardial infarction for thrombolytic therapy.

Authors:  D W Muller; E J Topol
Journal:  Ann Intern Med       Date:  1990-12-15       Impact factor: 25.391

7.  Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI).

Authors: 
Journal:  Lancet       Date:  1986-02-22       Impact factor: 79.321

8.  A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method.

Authors:  J R Beck; J P Kassirer; S G Pauker
Journal:  Am J Med       Date:  1982-12       Impact factor: 4.965

9.  Upper gastrointestinal haemorrhage in the elderly: a record of 92 patients in a joint geriatric/surgical unit.

Authors:  S K Bansal; P C Gautam; S P Sahi; S K Basu; J M Lennox; A J Warrington
Journal:  Age Ageing       Date:  1987-09       Impact factor: 10.668

10.  Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. AIMS Trial Study Group.

Authors: 
Journal:  Lancet       Date:  1990-02-24       Impact factor: 79.321

View more
  1 in total

1.  A meta-analysis of quality-of-life estimates for stroke.

Authors:  Tammy O Tengs; Ting H Lin
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.